Chronic hepatitis C: pathological anatomy

Mello, Evandro Sobroza de; Alves, Venâncio Avancini Ferreira

doi:10.1590/s1413-86702007000700010

Cited by 1 publication

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment is especially recommended for patients with a high probability of achieving sustained virological response (SVR), for patients with genotype 2 or genotype 3 and for patients infected with genotype 1 who have a low viral load (less than 400,000 to 500,000IU/ml) 9 . The treatment of choice for patients coinfected with HIV/HCV is PEG-interferon 10,11 in combination with ribavirin (RBV) at the same doses used in HIV-negative patients, independent of the viral genotype, with the presence of mild to severe fibrosis (F1 by the METAVIR or the Brazilian Society of Pathology classifications) 12 . The early virological response (EVR) and sustained virological response (SVR) rates are, however, lower in HIV-positive patients than in HIV-negative patients 13 .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the therapeutic response of hepatitis C in coinfected patients (HIV/HCV): a study of cases from a hospital for chronic liver diseases in the Eastern Brazilian Amazon

Amaral

Moia

Barbosa

et al. 2013

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

(1,000 to 1,250mg/day) for 48 weeks. The end point was the sustained virological response (SVR) rate (HCV RNA negative 24 weeks after completing treatment). Results: The mean age of the patients was 40±9.5 years, of which 89% (n=17) were male, and the HCV genotypes were genotype 1 (55%, n=11/20), genotype 2 (10%, n=2/20) and genotype 3 (35%, n=7/20). The mean CD4+ lymphocyte count was 507.8, and the liver fibrosis stages were (METAVIR) F1 (25%), F2 (55%), F3 (10%) and F4 (10%). The early virological response (EVR) was 60%, the end-of-treatment virological response (EOTVR) was 45% and the SVR was 45%. Conclusions: The median HCV viral load was high, and in 85% of cases in which highly active antiretroviral therapy (HAART) was used, none of the patients with F3-F4 fibrosis responded to treatment. Of the twenty patients treated, 45% achieved SVR and 45% achieved EOTVR. Studies that include cases from a wider region are needed to better evaluate these findings.

show abstract

Section: Introductionmentioning

confidence: 99%